學術發表 - OBI Pharma 台灣浩鼎

2023.Jan.26

ADC

First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

2022.Jun.22

Vaccine

The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer

2022.Jun.06

Vaccine

A phase 3, randomized, open-label study of the anti-Globo H vaccine Adagloxad Simolenin/OBI-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer

2022.Jun.05

ADC

First-in-Human Study of OBI-999: a Globo H-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors

2022.Jun.02

Prodrug

Safety, pharmacokinetics, and clinical activity of OBI-3424, an AKR1C3-activated prodrug, in patients with advanced or metastatic solid tumors: A phase 1 dose-escalation study.

2022.Apr.09

Vaccine

High Globo-H expression associated with poor survival of gastric cancer patients and enriched PD-L1 expression

2022.Apr.09

Prodrug

OBI-3424, an AKR1C3-activated prodrug, exhibits in vivo synergistic anti-tumor effect in combination with pembrolizumab by induction of immunogenic cell death

2021.Nov.04

Vaccine

The role of Globo H and SSEA-4 in the development and progression of cancer, and their potential as therapeutic targets

2021.Jul.15

Prodrug

A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity

2021.Jun.01

ADC

Preclinical Studies of OBI-999: A Novel Globo H–Targeting Antibody–Drug Conjugate